The European Society for Medical Oncology (ESMO), in collaboration with the Society for Immunotherapy of Cancer (SITC), is excited to announce a joint primer program and collaborative session at the 2024 ESMO Immuno-Oncology Congress.
we
Organizers:
- Tanja de Gruijl, PhD – VU University Medical Center
- Jarushka Naidoo, MB, BCH, MHS – Royal College of Surgeons in Ireland (RCSI)
we
Joint ESMO-SITC Immunotherapy Primer: Core Concepts of Immuno-Oncology Therapies
This program will provide an overview of the following topics: immunotherapy therapeutics (CPIs, TILs, CARs, vaccines, novel constructs and combinations), biomarkers of CPI, resistance to IO, immuno-toxicity, and IO in early stage cancers.
we
Chair/Moderator:
- Daniela S. Thommen, MD, PhD – Netherlands Cancer Institute
Faculty:
- George Coukos, MD, PhD – University Hospital of Lausanne
- Shubham Pant, MD, MBBS – MD Anderson Cancer Center
- Daniela S. Thommen, MD, PhD – Netherlands Cancer Institute
- Fatima Mechta-Grigoriou, PhD – Institut Curie
- Christina H. Ruhlmann, MD, PhD – Odense University Hospital
- Tanja de Gruijl, PhD – VU University Medical Center
ESMO-SITC Collaborative session: Alternative T Cell Subsets and Differentiation Pathways: Roles in Cancer and Immunotherapy
This session will discuss the roles of alternative t cell subsets and differentiation pathways in cancer immunotherapy. Talks will be provided on the following topics: mucosal associated T cells (MAITs), Vgamma9Vdelta2-T cells, and reprogramming T cell fates (exhaustion to activation).
we
Chair/Moderator:
- Andrea Schietinger, PhD – Memorial Sloan Kettering Cancer Center
Faculty:
- Oliver Lantz, PhD – Institut Curie
- Emmanuel Scotet, PhD – Institut National de la Santé et de la Recherche Médicale (INSERM)
- Andrea Schietinger, PhD – Memorial Sloan Kettering Cancer Center
To view the full ESMO Immuno-Oncology Congress program, click
here.